Please use this identifier to cite or link to this item:
https://doi.org/10.1161/JAHA.115.002197
DC Field | Value | |
---|---|---|
dc.title | Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF | |
dc.contributor.author | Pokorney, S.D | |
dc.contributor.author | Piccini, J.P | |
dc.contributor.author | Stevens, S.R | |
dc.date.accessioned | 2020-10-26T08:31:30Z | |
dc.date.available | 2020-10-26T08:31:30Z | |
dc.date.issued | 2015 | |
dc.identifier.citation | Pokorney, S.D, Piccini, J.P, Stevens, S.R (2015). Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF. Journal of the American Heart Association 5 (3) : e002197. ScholarBank@NUS Repository. https://doi.org/10.1161/JAHA.115.002197 | |
dc.identifier.issn | 20479980 | |
dc.identifier.uri | https://scholarbank.nus.edu.sg/handle/10635/180349 | |
dc.description.abstract | Background-Atrial fibrillation is associated with higher mortality. Identification of causes of death and contemporary risk factors for all-cause mortality may guide interventions. Methods and Results-In the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) study, patients with nonvalvular atrial fibrillation were randomized to rivaroxaban or dose-adjusted warfarin. Cox proportional hazards regression with backward elimination identified factors at randomization that were independently associated with all-cause mortality in the 14 171 participants in the intentionto- treat population. The median age was 73 years, and the mean CHADS2 score was 3.5. Over 1.9 years of median follow-up, 1214 (8.6%) patients died. Kaplan-Meier mortality rates were 4.2% at 1 year and 8.9% at 2 years. The majority of classified deaths (1081) were cardiovascular (72%), whereas only 6% were nonhemorrhagic stroke or systemic embolism. No significant difference in all-cause mortality was observed between the rivaroxaban and warfarin arms (P=0.15). Heart failure (hazard ratio 1.51, 95% CI 1.33-1.70, P<0.0001) and age ?75 years (hazard ratio 1.69, 95% CI 1.51-1.90, P<0.0001) were associated with higher all-cause mortality. Multiple additional characteristics were independently associated with higher mortality, with decreasing creatinine clearance, chronic obstructive pulmonary disease, male sex, peripheral vascular disease, and diabetes being among the most strongly associated (model C-index 0.677). Conclusions-In a large population of patients anticoagulated for nonvalvular atrial fibrillation, ?7 in 10 deaths were cardiovascular, whereas <1 in 10 deaths were caused by nonhemorrhagic stroke or systemic embolism. Optimal prevention and treatment of heart failure, renal impairment, chronic obstructive pulmonary disease, and diabetes may improve survival. © 2016 The Authors. | |
dc.rights | Attribution 4.0 International | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.source | Unpaywall 20201031 | |
dc.subject | creatinine | |
dc.subject | rivaroxaban | |
dc.subject | warfarin | |
dc.subject | anticoagulant agent | |
dc.subject | blood clotting factor 10a inhibitor | |
dc.subject | rivaroxaban | |
dc.subject | warfarin | |
dc.subject | age | |
dc.subject | aged | |
dc.subject | anticoagulant therapy | |
dc.subject | Article | |
dc.subject | atrial fibrillation | |
dc.subject | cardiovascular disease | |
dc.subject | cardiovascular mortality | |
dc.subject | cause of death | |
dc.subject | cerebrovascular accident | |
dc.subject | CHADS2 score | |
dc.subject | chronic obstructive lung disease | |
dc.subject | creatinine clearance | |
dc.subject | diabetes mellitus | |
dc.subject | embolism | |
dc.subject | female | |
dc.subject | heart failure | |
dc.subject | human | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | mortality | |
dc.subject | mortality rate | |
dc.subject | nonvalvular atrial fibrillation | |
dc.subject | peripheral vascular disease | |
dc.subject | priority journal | |
dc.subject | randomized controlled trial (topic) | |
dc.subject | sex difference | |
dc.subject | atrial fibrillation | |
dc.subject | blood | |
dc.subject | clinical trial | |
dc.subject | comorbidity | |
dc.subject | comparative study | |
dc.subject | complication | |
dc.subject | controlled study | |
dc.subject | double blind procedure | |
dc.subject | drug administration | |
dc.subject | intention to treat analysis | |
dc.subject | Kaplan Meier method | |
dc.subject | multicenter study | |
dc.subject | multivariate analysis | |
dc.subject | oral drug administration | |
dc.subject | proportional hazards model | |
dc.subject | randomized controlled trial | |
dc.subject | risk assessment | |
dc.subject | risk factor | |
dc.subject | Stroke | |
dc.subject | time factor | |
dc.subject | treatment outcome | |
dc.subject | very elderly | |
dc.subject | Administration, Oral | |
dc.subject | Age Factors | |
dc.subject | Aged | |
dc.subject | Aged, 80 and over | |
dc.subject | Anticoagulants | |
dc.subject | Atrial Fibrillation | |
dc.subject | Cause of Death | |
dc.subject | Comorbidity | |
dc.subject | Double-Blind Method | |
dc.subject | Drug Administration Schedule | |
dc.subject | Factor Xa Inhibitors | |
dc.subject | Female | |
dc.subject | Humans | |
dc.subject | Intention to Treat Analysis | |
dc.subject | Kaplan-Meier Estimate | |
dc.subject | Male | |
dc.subject | Multivariate Analysis | |
dc.subject | Proportional Hazards Models | |
dc.subject | Risk Assessment | |
dc.subject | Risk Factors | |
dc.subject | Rivaroxaban | |
dc.subject | Sex Factors | |
dc.subject | Stroke | |
dc.subject | Time Factors | |
dc.subject | Treatment Outcome | |
dc.subject | Warfarin | |
dc.type | Article | |
dc.contributor.department | MEDICINE | |
dc.contributor.department | SURGERY | |
dc.description.doi | 10.1161/JAHA.115.002197 | |
dc.description.sourcetitle | Journal of the American Heart Association | |
dc.description.volume | 5 | |
dc.description.issue | 3 | |
dc.description.page | e002197 | |
dc.published.state | Published | |
Appears in Collections: | Elements Staff Publications |
Show simple item record
Files in This Item:
File | Description | Size | Format | Access Settings | Version | |
---|---|---|---|---|---|---|
10_1161_JAHA_115_002197.pdf | 1.2 MB | Adobe PDF | OPEN | None | View/Download |
This item is licensed under a Creative Commons License